Samsung eyes wider foundry client base with Ambarella deal

Samsung Electronics Co., the world’s largest memory chipmaker, said on Tuesday it will manufacture automotive chips for US chip designer Ambar...

Samsung leader eyes memory chip packaging investment

Samsung Electronics Co., the world’s largest memory chipmaker, may accelerate investment in leading-edge technologies including chip packaging...

Korean shipbuilding, defense sectors offer bright 2023 outlook

South Korea’s major companies in shipbuilding, defense and construction industries expect strong earnings this year, despite growing concerns ...

AIMMED’s Somzz ushers in digital therapeutic device market in Korea

South Korea’s health and drug safety authority has cleared Somzz to treat patients with sleep disorders, a dynamic move that is expected to vi...

Vaxcell-Bio, Cellid sign MOU to build cancer immunotherapy platform

Vaxcell-Bio Therapeutics, a South Korean company specializing in anti-cancer immunotherapy, announced on Wednesday its partnership with Cellid Co. t...

HK inno.N's GERD drug K-CAB gets approval in Mexico

South Korea's biohealth company HK inno.N said on Tuesday that its gastroesophageal reflux disease (GERD) treatment K-CAB (active ingredient: tegopr...

SK Plasma, Janssen Korea sign sales, distribution agreement

SK Plasma Co. Ltd., a South Korean company specializing in the production of plasma derivatives from human plasma, is expanding its product portfoli...

Samsung, SK Hynix: key beneficiaries of ChatGPT fever

Samsung Electronics Co. and SK Hynix Inc., the world’s two largest memory chipmakers, stand to benefit from the global popularity of ChatGPT. ...

Hanall Biopharma invests in Interon Labs for brain disease treatments

South Korean pharmaceuticals firm Hanall Biopharma Co. is investing in Interon Laboratories, a US biotech firm that finds and develops treatments fo...

HLB’s Rivoceranib, Hengrui's Camrelizumab approved as combination therapy in China

South Korea's HLB Co. announced on Thursday that the combination therapy of its drug candidate rivoceranib and Jiangsu Hengrui Pharmaceuticals Co., ...

Prestige Bio's Herceptin biosimilar proves equivalence in clinical trials

Prestige Biopharma, a South Korean biopharmaceutical developer, said on Tuesday that the final analysis of phase 3 clinical trial on the anti-cancer...

SKC eyes M&As in semiconductor, rechargeable battery materials

SKC Inc., a South Korean chemical materials company under SK Group, is seeking to buy semiconductor and rechargeable battery materials companies in ...

Hanmi's Rolvedon set to post $10 mn in Q4 net sales in US

South Korean drugmaker Hanmi Pharmaceutical Co.’s neutropenia agent, Rolvedon (eflapegrastim-xnst), is forecast to achieve about $10 million i...

LG Elec eyes profit from EV powertrain, car lighting biz

LG Electronics Inc., the world’s leading home appliance maker, aims to take profit from the electric vehicle powertrain and car lighting units...

Samsung vows no chip output cut, eyes second-half demand recovery

Samsung Electronics Co. said on Tuesday it has no plans to cut semiconductor production even if it incurs temporary losses as the world’s larg...

GM Korea to launch Trax, Cadillac EV; likely turn to profit this year

GM Korea Co. expects to turn to profit this year after years of losses as the South Korean subsidiary of the US auto giant plans to bring six new an...

Samsung seeks to sell more smartphones in Southeast Asia

Southeast Asia is an attractive smartphone market for both heavyweights and mass-market players given the relatively large number of young people wh...

Bridge Biotherapeutics, Pinotbio develop lung cancer treatment

South Korea's biotech companies Bridge Biotherapeutics Inc. and Pinotbio on Thursday said they will jointly develop new antibody-drug conjugates (AD...

Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan

Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizum...

HK inno.N to introduce biosimilars for bone disease treatment from Spain

South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to intr...

Inventage Lab launches clinical trials for addiction treatment in Australia

South Korea's Inventage Lab, a developer of a drug delivery system platform, on Wednesday said it received approval from the Human Research Ethics C...

ST Pharm exports $14.6 mn worth of drug ingredients to Europe

ST Pharm Co., a South Korean company specializing in contract development and manufacturing of drug ingredients, has signed a supply contract worth ...

LG Chem completes acquisition of US biotech firm AVEO

LG Chem Ltd. is set to complete its $571 million purchase of the US biotech firm AVEO Pharmaceuticals Inc. on Friday, which would strengthen its ant...

GC Biopharma's Sanfilippo treatment eligible for FDA priority review

GC Biopharma Corp. said on Wednesday that its Sanfilippo type A treatment, which is under joint development with Novel Pharma, a bio-venture special...

BC Card eyes Central Asian payment market entry this year

South Korea's financial services company BC Card said on Wednesday that it would seek to enter the Central Asian market this year on the back of its...

MedPacto's anti-cancer substance designated as US FDA fast-track item

South Korean biotech company MedPacto Inc. ’s Vactosertib monotherapy for osteosarcoma patients has been designated as a fast-track developmen...

Celltrion applies for EMA approval of smaller dose formulation of Yuflyma

Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...

SK Chemicals launches uremia itching treatment tablet

SK Chemicals said on Monday that it has launched Remitch in orally disintegrating tablets, a treatment for intractable uremic pruritus (uremia itchi...

Korea eyes removal of pre-reporting for forex transactions

South Korea as early as the second half of next year could lift regulations on money transfers abroad that exceed $50,000 per year.Daily foreign cur...

SK Inc. eyes significant growth in bio business from 2024

SAN FRANCISCO – SK Inc.,  the investment and holding company of South Korea’s SK Group, expects significant growth in its biopharma...